Search the web
Welcome, Guest
[Sign Out, My Account]
 EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI 		Symbol Lookup | Financial Search
NLNK > SEC Filings for NLNK > Form 8-K on 13-Dec-2012All Recent SEC Filings

Show all filings for NEWLINK GENETICS CORP | Request a Trial to NEW EDGAR Online Pro

Form 8-K for NEWLINK GENETICS CORP

13-Dec-2012

Other Events


Item 8.01. Other Events.

On December 13, 2012, NewLink Genetics (NASDAQ:NLNK) announced that the results of a Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy. The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens," is featured in the current edition of the Journal.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

  Add NLNK to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for NLNK - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.